Skip to main content
 

Evie Faure
Click to enlarge

Evie Faure

 Senior Engagement Manager

Evie works in RIG’s Decarbonisation and Circular Economy Practice, focusing on Energy Transition and Materials.

She joined from a biotech company pioneering mycelium-based materials, where she led early stage commercial strategy. Evie brings experience in business development, strategic partnerships, licensing and investor engagement within the climate tech and biomaterials sectors. Supported by a Biotechnology with Enterprise degree from the University of Manchester, Evie has a particular interest in ventures that deliver tangible regenerative outcomes and is motivated by supporting teams working on solutions for systemic environmental challenges.

A native French speaker with some rusty Spanish, Evie enjoys travel, tennis, cooking, and growing veg!

The Importance and Value of Creating an ICP

An ‘Ideal Customer Profile’ (ICP) is a tool we often use at RIG - a set of narrowly defined hypotheses that pinpoints the type of customer most suited for utilising the technology that is being commercialised.

 

The Potential of Fungi

The global mycelium market is expected to grow at a CAGR of 7.3% to reach $5.5 Billion by 2030, according to InsightAce Analytic. The market is booming, with biotechnology startups and investors entering the space due to its various applications for the Food & Beverage, Animal Feed, Packaging, Clothing and Apparel industries. Rapid Innovation’s AgBio team envision a fundamental shift in the Food & Beverage and Animal Feed industries in this decade on the back of emerging applications and products from the fungi kingdom.

 

Becoming Supply Chain Savvy

It could be assumed that a soil carbon measurement technology would be most attractive to farmers, however, it is apparent that the entire supply chain needs to be addressed and connected, otherwise an opportunity might be missed.

 

The Role of Bacteriophage in the Fight Against AMR

No action today, no cure tomorrow

 

The Valley of Death for New Medicines

The biotechnology sector is filled with the promise of new cancer treatment approaches, such as immunotherapy, but the financial stumbling blocks could prevent these advances from reaching patients.